Nxera Announces Focused Restructuring to Enhance Path to Profitability

Executive Summary

• Nxera Pharma announced a focused restructuring to concentrate resources on high‑value GPCR platforms, targeting JPY 50 bn net sales and ~30% operating margin by 2030.
• FY2026 R&D spend in the UK will be cut by roughly JPY 3.5 bn; workforce reductions of ~15% in Japan and the UK are planned, with a one‑time restructuring charge of about JPY 500 m in FY2025.
• Dr. Patrik Foerch appointed Chief Scientific Officer & President of Nxera Pharma UK; executive team reduced from 10 to 7 members by March 2026.

Key Details

• Restructuring Objectives – Prioritize GPCR‑focused programs, leverage the AI‑enabled NxWave™ platform, and streamline leadership and workforce.
• R&D Cost Reduction – FY2026 cash R&D expenditure in Cambridge to be lowered by ~JPY 3.5 bn; expected year‑on‑year savings of at least JPY 1.0 bn from FY2026 onward.
• Workforce Impact – Approx. 15% headcount reduction across Japan and UK operations; no impact on Swiss or South Korean sites.
• One‑Time Charges – Anticipated restructuring expense of ~JPY 500 m to be recorded in FY2025 as non‑core operating costs.
• Executive Changes – Dr. Patrik Foerch named CSO & President, Nxera Pharma UK (effective 3 Oct 2025); executive team trimmed from ten to seven members by Mar 2026.
• Cash Position – Current cash and liquid investments of JPY 30.9 bn provide flexibility for the restructuring plan.
• Program Highlights – Ongoing progress on partnered GPCR programs:
• Neurocrine’s Direclidine (M4 agonist) moving to Phase 3 in 2025; new Phase 2 bipolar mania study Q4 2025.
• Centessa’s ORX750 (orexin‑2 agonist) showing promising Phase 2a data; registrational program slated for Q1 2026.
• NXE’732 (EP4 antagonist) completed Phase 1, entering Phase 2 expansion with Cancer Research UK.
• NXE’149 (GPR52 agonist) to finish Phase 1 by year‑end; licensing decision imminent with Boehringer Ingelheim.
• Compensation Adjustments – FY2025 performance‑linked cash bonuses for executives will be materially reduced; final amounts to be set by the Compensation Committee in Jan 2026.

Notable Quotes

“The actions we are announcing today will simplify how we work, accelerate momentum in programs with clear clinical and commercial potential and strengthen our operating leverage.” – Chris Cargill, President & CEO

“I am delighted to welcome Patrik to the team… his expertise in building AI drug discovery platforms is expected to support enhanced portfolio decision making…” – Chris Cargill, President & CEO